CD19 and neoplasm: Anti-CD19-NSCAR transduced into γδ T cells was able to increase target-specific tumor cell killing 1.5-fold compared to UT cells, and depicted minimal cytotoxicity against healthy B-lymphocytes comparable to UTs [220].